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Background: Myocardial extracellular volume (ECV) is elevated in fibrosis or infiltration and can be quantified by
measuring the haematocrit with pre and post contrast T1 at sufficient contrast equilibrium. Equilibrium CMR
(EQ-CMR), using a bolus-infusion protocol, has been shown to provide robust measurements of ECV using a
multibreath-hold T1 pulse sequence. Newer, faster sequences for T1 mapping promise whole heart coverage and
improved clinical utility, but have not been validated.
Methods: Multibreathhold T1 quantification with heart rate correction and single breath-hold T1 mapping using
Shortened Modified Look-Locker Inversion recovery (ShMOLLI) were used in equilibrium contrast CMR to generate
ECV values and compared in 3 ways.
Firstly, both techniques were compared in a spectrum of disease with variable ECV expansion (n=100, 50 healthy
volunteers, 12 patients with hypertrophic cardiomyopathy, 18 with severe aortic stenosis, 20 with amyloid).
Secondly, both techniques were correlated to human histological collagen volume fraction (CVF%, n=18, severe
aortic stenosis biopsies). Thirdly, an assessment of test:retest reproducibility of the 2 CMR techniques was performed
1 week apart in individuals with widely different ECVs (n=10 healthy volunteers, n=7 amyloid patients).
Results: More patients were able to perform ShMOLLI than the multibreath-hold technique (6% unable to breath-hold).
ECV calculated by multibreath-hold T1 and ShMOLLI showed strong correlation (r2=0.892), little bias (bias -2.2%, 95%CI
-8.9% to 4.6%) and good agreement (ICC 0.922, range 0.802 to 0.961, p<0.0001). ECV correlated with histological CVF%
by multibreath-hold ECV (r2= 0.589) but better by ShMOLLI ECV (r2= 0.685). Inter-study reproducibility demonstrated that
ShMOLLI ECV trended towards greater reproducibility than the multibreath-hold ECV, although this did not reach
statistical significance (95%CI -4.9% to 5.4% versus 95%CI -6.4% to 7.3% respectively, p=0.21).
Conclusions: ECV quantification by single breath-hold ShMOLLI T1 mapping can measure ECV by EQ-CMR across the
spectrum of interstitial expansion. It is procedurally better tolerated, slightly more reproducible and better correlates with
histology compared to the older multibreath-hold FLASH techniques.
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The myocardial extracellular space is expanded by focal
fibrosis [1], diffuse fibrosis [2-6] or infiltration, such as
amyloidosis [7]. It can be measured non-invasively by
cardiovascular magnetic resonance (CMR) using pre and
post contrast T1 relaxation times of blood and myocar-
dium (the latter at sufficient contrast equilibrium) with
correction for the blood volume of distribution via the
haematocrit [1,2,8]. A number of T1 measurement techni-
ques exist including multibreath-hold techniques such fast
low angle single shot inversion recovery (“multibreath-
hold FLASH-IR”). Here the sequence is performed at
increasing inversion times to generate T1 recovery
curves and heart rate correction [9,10]. Newer, faster
sequences such as MOLLI (Modified Look-Locker In-
version recovery) [11] perform IR measurements in a
single breath-hold. A recent evolution of MOLLI, the
Shortened-MOLLI (ShMOLLI) [12] improves clinical
utility with a shorter breath-hold and immediate map
reconstruction directly on the scanner. ECV measure-
ments have been performed and validated using MOLLI
for bolus-only protocols. Equilibrium contrast CMR
(EQ-CMR) with single breath-hold sequences has not
yet been validated for ECV assessment. ECV mapping
with such sequences would be a significant technical
advance, being easier for patients with shorter breath-
holds (either shorter scans or whole heart coverage)
and easier quantification.
We hypothesised that ECV mapping using ShMOLLI
would be superior to the multibreath-hold FLASH-IR
technique. This was assessed in three ways: firstly, to de-
termine any bias in ECV between the two techniques.
Secondly, we compared both CMR techniques with
histological collagen volume fraction (CVF%). Finally, we
assessed the reproducibility of both CMR techniques.
For equivalence of contrast conditions between the two




The research received approval from the local research
ethics committee and all participants provided written
informed consent. EQ-CMR was performed as described
previously [9]. CMR was performed on a 1.5T magnet
(Avanto, Siemens Medical Solutions). Within a standard
clinical scan (pilots, transverse white and black blood
images, volumes, and LGE imaging) T1 measurement
pre-contrast was performed using (a) FLASH-IR at in-
creasing inversion times from 140 to 800 ms (or 900 ms
if patient heart rate permitted), “multibreath-hold tech-
nique”, Figure 1a and (b) ShMOLLI T1 mapping “single
breath-hold technique”, Figure 1b. After a bolus of
Gadoterate meglumine, (0.1 mmol/kg, gadolinium-DOTA, marketed as Dotarem © Guerbet S.A. France)
and standard LGE imaging, at 15-minute post bolus, an
infusion at a rate of 0.0011 mmol/kg/min contrast
(equivalent to 0.1 mmol/kg over 90 minutes) was given.
The patient was typically removed from the scanner at
this time. At between 45 minutes and 80 minutes post
bolus, the patient was returned to the scanner, still with
the infusion, and the T1 measurement repeated using
both multi and single breath-hold techniques. Separate
regions of interest (ROIs) were placed in all available
images and recovery curve was reconstructed by fitting
the relaxation formula to ROI averages. Heart rate cor-
rection was used for the multibreath-hold technique [9].
In the ShMOLLI sequence, T1 maps were generated
using previously published algorithm [12]. A single ROI
was drawn directly in each T1 map at the same location
as the multibreath-hold technique and T1 averaged be-
tween all pixels (Figure 1b). A haematocrit was taken in
all subjects. The ECV was calculated with each method
as Myocardial ECV = (1-haematocrit) × (ΔR1myocardium/
ΔR1blood) [1]. T1 was measured in the basal to mid
septum avoiding areas of late gadolinium enhancement,
except in myocardial infarction (where the infarct zone
was assessed) and amyloid (where the regions was drawn
irrespective of the ill-defined presence/absence of LGE).
The blood T1 was assessed in the descending aorta. All
the analysis were performed blinded.
Patient studies: healthy normal subjects and disease
groups
Normal subjects (n=50, median age 47±17, 53% male)
were recruited through advertising within the hospital,
university and general practitioner surgeries. All normal
subjects had no history or symptoms of cardiovascular
disease or diabetes. Four subjects had been prescribed
statin therapy for hypercholesterolaemia (primary car-
diovascular prevention), but no other normal subject
was taking any cardiovascular medication. All subjects
had a normal blood pressure, 12 lead electrocardiogram
and clinical CMR scan.
Patients (n=50) were prospectively recruited from ter-
tiary clinical and research departments at the Heart Hos-
pital or the National Amyloidosis Centre, Royal Free
Hospital: [1] 12 patients with hypertrophic cardiomyop-
athy meeting the diagnostic criteria (average age 52±13,
60% male). [2] 18 patients with severe aortic stenosis
waiting for aortic valve replacement (median age: 71±10,
72% male). [3] 20 patients with cardiac AL amyloidosis
with disease proven by non-cardiac biopsy and cardiac
involvement ascertained through echocardiography, sup-
ported by a Mayo clinic classification score of 2 or 3
(average age: 60±10, 75% male). Patients with atrial fib-
rillation or a contra-indication to contrast CMR examin-
ation were excluded from the study.
Table 1 Mean ECV ± standard deviation assessed using
multibreath-old T1 quantification and ShMOLLI T1 in





Normal subjects (n=50) 26±3 27±3
HCM (n=12) 28±4 30±3
AS (n=18) 27±6 31±5
Amyloid (n=20) 48±6 52±7
Figure 1 Pre contrast T1 measurement example. Left multiple panels: The multibreath-hold T1 measurement uses up to 7 CMR acquisitions
with linearly increasing inversion time. T1 value is reconstructed from fitting average signal intensity from individual image intensity averages.
Right single panel: ShMOLLI technique generates T1 map directly on the scanner console using pixelwise calculations based on a single
breath-hold experiment. ShMOLLI T1 is calculated as average of all pixels from a region of interest drawn in the myocardium.
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24 patients with severe aortic stenosis listed for surgical
aortic valve replacement were studied. An intraoperative
deep myocardial biopsy (Tru-Cut needle) was taken in aor-
tic stenosis. Samples were stained and analysed for CVF%,
as previously described [9]. 6 patients were excluded from
further analysis (2 patients had focal fibrosis detected as
LGE in the basal septum; 2 patients had biopsies consist-
ing solely of endocardial fibrosis; in 1 patient multibreath-
hold T1 quantification was not performed because the pa-
tient was unable to breath-hold; 1 patient had a pulmonary
oedema during the scan) leaving 18 patients.
Reproducibility
For test:retest interstudy reproducibility, 10 normal sub-
jects and 7 patients with amyloid underwent repeat
scanning, one week apart. The analysis was carried out
by a single observer blinded.
Data analysis and statistics
Results were analysed using SPSS (Chicago, IL, USA,
version 19). ECV values were found to be normally dis-
tributed in each group (Kolmogorov-Smirnov test,
p>0.05 for each data set) and so expressed as mean ±
standard deviation. We used Intraclass Correlation Coef-
ficient (ICC) and Bland-Altman plot to compare ECV
values from the two methods. Interstudy reproducibility
for the CMR measurement of ECV was assessed by cal-
culating the ICC and Bland Altman plots. To compare
the squared difference of paired ECV measurements
Wilcoxon signed rank test was used. A p value <0.05
was considered statistically significant.Results
ECV comparison
No patients failed ShMOLLI acquisition. 6% of patients
were unable to perform all the 14 breath-holds required
for the multibreath-hold technique. The mean ECV
assessed using multibreath-hold T1 quantification and
ShMOLLI T1 in normal subjects and disease groups is
shown in Table 1. ECV by multibreath-hold T1 quantifi-
cation and by ShMOLLI T1 mapping showed excellent
correlation (r2=0.892) and agreement across disease
groups (overall ICC 0.922, 95%CI 0.802 to 0.961,
p<0.0001), Figure 2a, with little bias on Bland Altman
(bias -2.2%, 95%CI -8.9% to 4.6%), Figure 2b.
Histological validation
All biopsies were uneventful. The mean histological CVF
of the 18 biopsies was 18% ± 8% (range 7% to 40%). There
was a strong correlation between histological CVF% and
FLASH ECV (r2= 0.589) but this was stronger with
ShMOLLI ECV (r2= 0.685) (Figure 3).
Figure 2 Sh-MOLLI and multibreath-hold ECV correlation in health and disease (panel a) and the same data plotted as a Bland-Altman
analysis (panel b), showing little bias.
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Inter-study reproducibility demonstrated that ShMOLLI
ECV was slightly more reproducible than the multibreath-
hold ECV, Figure 4, (ICC 982, 95%CI 0.951-0.994 versus
ICC 962, 95%CI 0.897-0.987), with narrower confidence
intervals (95%CI -4.9% to 5.4% versus 95%CI -6.4% to
7.3% respectively). Neither of these reached statistical
significance however, P>0.2.
Discussion
CMR ECV quantification requires accurate and rapid
T1 relaxation time calculation. We have found that
ECV quantification using ShMOLLI compared to
multibreath-hold T1 quantification has a greater chance
of technical success on all patients, less bias over a wide
range of ECV measurements, a higher correlation with
histological CVF% as well as better reproducibility.
These four findings combine with key advantages of theFigure 3 ECV against histological CVF% (n=18) by ShMOLLI (panel a)mapping technique: a single breath-hold per T1 map,
simple analysis and the potential for whole heart ECV
quantification. Therefore, it is our opinion that T1 map-
ping technique ShMOLLI is the superior CMR tech-
nique for ECV quantification.
T1 mapping by means of the multi-breath-hold tech-
nique is one of the most commonly utilised methods for
T1 quantification [9,10]. The main advantage of this
technique is that it is not vendor specific and it has been
heavily optimised by everyday clinical practice to obtain
high resolution LGE images. However it also has a num-
ber of limitations. Firstly, in order to map a single car-
diac slice, it requires the sequence to be run up to 9
times at increasing inversion times. The average breath-
hold time for each sequence is 14 seconds (longer at
slower heart rates). If the patient cannot hold their
breath for the duration of the sequence, artefact will ap-
pear on any one of the images. This may also occur ifand multi-breath-hold (panel b).
Figure 4 Bland-Altman analysis to express the intrasequence reproducibility of the myocardial T1 values using FLASH-IR (panel a) and
ShMOLLI (panel b) in normal subjects (blu square) and amyloid patients (orange square). The limits of agreement are slightly narrower for
ShMOLLI than multibreath-hold.
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many breath-holds to map, this method can not be used
clinically for whole heart mapping (i.e. of multiple car-
diac slices). Once the images have been obtained, the
offline post processing is laborious and the results re-
quire heart rate correction for the calculated T1 relaxa-
tions times [9].
We have found that ECV quantification using ShMOLLI
improves on several practical aspects compared to
multibreath-hold T1 quantification. ShMOLLI imaging is
characterised by lower breath-hold failure rate, less bias
over a wide range of ECV, a slightly higher correlation
with histological collagen volume fraction and slightly bet-
ter reproducibility, although it does not reach statistical
significance. Shorter acquisition times and direct T1 map
calculation on the scanner [12] ensures ShMOLLI is
quicker to perform and analyse with a potential to pro-
vide whole heart ECV quantification. While currently
ShMOLLI is vendor specific, its predecessor MOLLI exists
for more than one platform [13].
Future techniques for T1 measurement are likely to be
based on mapping. Further advances may include higher
resolution imaging with reduction of partial volume
effects, with that incorporate motion correction and
improved capabilities for measuring longer T1s [14-17].
We preferred here to re-iterate the T1 map for max-
imum accuracy – a step that will likely be un-necessary
in future refinements. Preliminary exploration is being
made of combining the two T1 maps into an ECV map
using further non-rigid registration [10].
This study has limitations. We have not presented the
phantom work comparing ShMOLLI and FLASH-IR T1
estimation as this was primarily an ECV clinically-
orientated paper with many of the likely confounders
present only in-vivo and not detectable by phantom
work. Histology correlations were lower previouslydescribed [9]. We believe this is primarily due to differ-
ent population characteristics (the population examined
here is older) and to a greater number of surgeons
involved in the biopsy arm of this study (with associated
reduced homogeneity of samples). Finally, FLASH-IR
was compared to a single T1 mapping technique,
ShMOLLI. MOLLI,its variants and other T1 mapping
techniques such as SACHA [18] were not considered in
this study.
As ECV quantification experience increases, it is likely
that technology will advance to become more precise,
accurate and automated. Our study represents the first
such paper and demonstrates that single breath-hold
ShMOLLI T1 mapping can quantify ECV by EQ-CMR
across the spectrum of interstitial expansion, and that
it is clinically more straightforward with improve-
ments in reproducibility and histological correlation
when compared to the older multibreath-hold FLASH
techniques.
Conclusion
ECV quantification by single breath-hold ShMOLLI T1
mapping can measure ECV by EQCMR across the
spectrum of interstitial expansion. It is procedurally better
tolerated, slightly more reproducible and better correlates
with histology compared to the older multibreathhold
FLASH techniques.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
MF: led the study; co-ordinated analysis; lead writer of manuscript. SKW, SMB,
DMS, VM each contributed a patient group along with the respective
analysis. SKP & SN: technical support for T1 mapping sequence/ShMOLLI
development, analysis of T1 maps. ASF: blind analysis of histological data. NR:
co-ordinated the surgical support and biopsy. JCM: concept and design of
study. All authors read and approved the final manuscript.
Fontana et al. Journal of Cardiovascular Magnetic Resonance 2012, 14:88 Page 6 of 6
http://www.jcmr-online.com/content/14/1/88Acknowledgements
This work was undertaken at UCLH/UCL who received a proportion of
funding from the Department of Health's NIHR Biomedical Research Centres
funding scheme. SN and SKP acknowledge support from the National
Institute for Health Research Oxford Biomedical Research Centre Programme.
JCM is funded by HEFCE. SKW, DMS, ASF are funded by the British Heart
Foundation. SN also acknowledges support from the Oxford British Heart
Foundation Centre of Research Excellence.
Disclosures
US patent pending 61/387,591: SKP. SYSTEMS AND METHODS FOR SHORTENED
LOOK LOCKER INVERSION RECOVERY (Sh-MOLLI) CARDIAC GATED MAPPING OF
T1. September 29, 2010. All rights sold exclusively to Siemens Medical. All the
other authors declare that they have no competing interests.
Author details
1The Heart Hospital, 16-18 Westmoreland Street, London W1G 8PH, United
Kingdom. 2Institute of Cardiovascular Science, University College London,
London WC1E 6BT, United Kingdom. 3Department of Cardiovascular
Medicine Oxford Centre for Clinical Magnetic Resonance Research, University
of Oxford, Oxford OX3 9DU, United Kingdom.
Received: 26 June 2012 Accepted: 19 December 2012
Published: 28 December 2012
References
1. Arheden H, Saeed M, Higgins CB, Gao DW, Bremerich J, Wyttenbach R, Dae
MW, Wendland MF. Measurement of the distribution volume of
gadopentetate dimeglumine at echo-planar MR imaging to quantify
myocardial infarction: comparison with 99mTc-DTPA autoradiography in
rats. Radiology. 1999; 211:698–708.
2. Moon JC. Myocardial tissue characterisation using gadolinium CMR:
University of London Library; 2005. Chapter 12.
3. Ugander M, Oki AJ, Hsu LY, Kellman P, Greiser A, Aletras AH, Sibley CT, Chen
MY, Bandettini WP, Arai AE. Extracellular volume imaging by magnetic
resonance imaging provides insights into overt and sub-clinical
myocardial pathology. Eur Heart J. 2012; 33:1268–78.
4. Flett AS, Sado DM, Quarta G, Mirabel M, Pellerin D, Herrey AS, Hausenloy DJ, Ariti
C, Yap J, Kolvekar S, Taylor AM, Moon JC. Diffuse myocardial fibrosis in severe
aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance
study. Eur Heart J Cardiovasc Imaging. 2012; 13:819–26.
5. Jerosch-Herold M, Sheridan DC, Kushner JD, Nauman D, Burgess D, Dutton
D, Alharethi R, Li D, Hershberger RE. Cardiac magnetic resonance imaging
of myocardial contrast uptake and blood flow in patients affected with
idiopathic or familial dilated cardiomyopathy. Am J Physiol Heart Circ
Physiol. 2008; 295:H1234–H42.
6. Sado DF, Banypersad A, White S, Maestrini S, Quarta V, Lachmann G, Murphy R,
Mehta E, Hughes A, McKenna D, Taylor W, Hausenloy A, Hawkins D, Elliott P,
Moon J. Cardiovascular magnetic resonance measurement of myocardial
extracellular volume in health and disease. Heart. 2012; in Press.
7. Banypersad S, Sado D, Flett A, Gibbs SD, Pinney JH, Maestrini V, White SK,
Dungu J, Hawkins PN, Moon JC. Cardiac involvement in cardiac AL
amyloidosis as measured by equilibrium contrast cardiovascular
magnetic resonance [abstract]. JCMR. 2012; 14(suppl 1):P174.
8. Schelbert EB, Testa SM, Meier CG, Ceyrolles WJ, Levenson JE, Blair AJ,
Kellman P, Jones BL, Ludwig DR, Schwartzman D, Shroff SG, Wong TC.
Myocardial extravascular extracellular volume fraction measurement by
gadolinium cardiovascular magnetic resonance in humans: slow infusion
versus bolus. J Cardiovasc Magn Reson. 2011; 4:13–6.
9. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM,
McGregor C, Moon JC. Equilibrium contrast cardiovascular magnetic
resonance for the measurement of diffuse myocardial fibrosis: preliminary
validation in humans. Circulation. 2010; 122:138–44.
10. White SK, Sado DM, Flett AS, Moon JC. Characterising the myocardial
interstitial space: the clinical relevance of non-invasive imaging. Heart.
2012; 98:773–9.
11. Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway
JP. Modified look-locker inversion recovery (MOLLI) for high-resolution T1
mapping of the heart. Magn Reson Med. 2004; 52:141–6.
12. Piechnik SK, Ferreira VM, Dall'Armellina E, Cochlin LE, Greiser A, Neubauer S,
Robson MD. Shortened modified look- locker inversion recovery (ShMOLLI)for clinical myocardial T1-mapping at 1.5 And 3 T within a 9 heartbeat
breathhold. J Cardiovasc Magn Reson. 2010; 12:69.
13. Messroghli DR, Rudolph A, Abdel-Aty H, Wassmuth R, Kühne T, Dietz R,
Schulz-Menger J. Open-source software tool for the generation of
relaxation time maps in magnetic resonance imaging. BMC Med Imaging.
2010; 10:16.
14. Lee JJ, Liu S, Nacif MS, Ugander M, Han J, Kawel N, Sibley CT, Kellman P, Arai
AE, Bluemke DA. Myocardial T1 and extracellular volume fraction mapping
at 3 Tesla. J Cardiovasc Magn Reson. 2011; 28:13–75.
15. Xue H, Shah S, Greiser A, Guetter C, Littmann A, Jolly MP, Arai AE,
Zuehlsdorff S, Guehring J, Kellman P. Motion correction for myocardial T1
mapping using image registration with synthetic image estimation.
Magn Reson Med. 2012; 67:1644–55.
16. Kawel N, Nacif M, Zavodni A, Jones J, Liu S, Sibley CT, Bluemke DA. T1
Mapping of the myocardium: intra-individual assessment of the effect
of field strength, cardiac cycle and variation by myocardial region.
J Cardiovasc Magn Reson. 2012;1;14(1):27.
17. Kawel N, Marcelo N, Anna Z, Jacquin J, Songtao L, Sibley CT, Bluemke DA. T1
Mapping of the myocardium: intra-individual assessment of post-contrast
T1 time evolution and extracellular volume fraction at 3T for Gd-DTPA and
Gd-BOPTA. J Cardiovasc Magn Reson. 2012; 14(issue number):26. doi:10.1186/
1532-429X-14-26.
18. Chow K, Flewitt JA, Pagano JJ, Green JD, Friedrich MG, Thompson RB. MOLLI




Cite this article as: Fontana et al.: Comparison of T1 mapping techniques
for ECV quantification. Histological validation and reproducibility of
ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast
CMR. Journal of Cardiovascular Magnetic Resonance 2012 14:88.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
